Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Cancer Survivorship Issues: A Survey of Patients in India.AIIMS Study (CANSURVIVE) (CANSURVIVE)

11 luglio 2012 aggiornato da: Bidhu Kalyan Mohanti, All India Institute of Medical Sciences, New Delhi

The purpose of this study is to assess the various aspects of life in the cancer survivors in India. Cancer survivor is defined as "an individual diagnosed with cancer and who has survived the disease and treatment, and for the rest of his/her life".

Cancer survivors are at increased risk of developing various physical and psychosocial conditions, which require to be identified and attended within the cancer care system.

Survivorship research is seen as addressing the medical, functional, and health related issues of individuals diagnosed with cancer, as well as that of their families.

Panoramica dello studio

Stato

Sconosciuto

Condizioni

Descrizione dettagliata

It is estimated that approximately 25 million people are living as cancer survivors worldwide. The cancer survivors are those individuals who live beyond a cancer diagnosis and its therapy. Within the existing health care system, the cancer care models are largely focused on diagnostic methods, treatment aspects, cure, and disease failure and survival rates. There is very little research and intervention approaches for the after-effects of cancer diagnosis and treatments for an individual cancer patient. Cancer survivors are at increased risk of developing various physical and psychosocial conditions, which require to be identified and attended within the cancer care system. In the developing countries like India, the cancer cure rates are improving due to improvements in comprehensive diagnostic and treatment strategies. Cancer survivorship research will be valuable to enhance our understanding and care approaches to these vulnerable individuals in our society. There is lack of evaluation tools which can completely fit to assess all issues such as physical, social, financial, mental aspects of a cancer survivor.

Hence the investigators of this observational study have prepared an empirical cancer survivorship questionnaire (CSQ) which will document the patient's disease and treatment details and obtain subjective responses from the patient(and/or family care giver) related to the physical, functional, social, economic and mental aspects of daily living of a cancer survivor. In order to assess the mental status of the survivors, the investigators have also included the widely used and internationally accepted MINI (Mini-international neuropsychiatry interview) version along with the CSQ in this survey. Researchers and clinicians working in non-profit and academic setting such as this institution are allowed to make copies of this MINI questionnaire for the purpose of clinical and research use. For the present study, MINI version is suitably modified to exclude the items which are already in the CSQ, and certain items are reframed for the socio-cultural requirement. Both the CSQ (45 items) and MINI-modified (13 items) will be applied simultaneously in this survey as a direct face to face response documentation from the patient (cancer survivor), along with his/her family member. Patients will be chosen for this cross-sectional survey during the follow-up visit to a cancer clinic of this hospital, at least 3 months after the completion of cancer diagnosis and therapy. Each participant is expected to complete the survey at the first encounter, however, a provision is made to report any missing information at later visit.

An interim analysis will be carried out after the survey of first 50 patients to observe the trends in the findings. However, this will not impact the further accrual, except for making some changes in the survey parameters if at all needed.

Tipo di studio

Osservativo

Iscrizione (Anticipato)

200

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Delhi
      • New Delhi, Delhi, India, 110029
        • Reclutamento
        • All India Institute of Medical Sciences Dr.B.R.A.Institute Rotary Cancer Hospital
        • Contatto:
        • Contatto:
        • Investigatore principale:
          • BIDHU K MOHANTI, MD

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 75 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Metodo di campionamento

Campione non probabilistico

Popolazione di studio

This study will evaluate the cancer patients visiting Dr BRAIRCH,AIIMS,New Delhi,India after a cancer diagnosis and the cancer treatments have been completed.

The patients will be entered into this study(survey) during the follow up visits to the clinic.

Patients will be evaluated and assessed for their cancer survivorship issues on the basis of a questionnaire (CSQ) developed by the investigators after the literature review. The mental status of the survivors is assessed by a MINI- international neuro-psychiatric interview, suitably modified to incorporate the CSQ in this survey.

Descrizione

Inclusion Criteria:

  • Patients who were treated with curative intent and are on hospital follow up visit.
  • Patients aged above 18 years and of both sexes.
  • Patients who have no evidence of disease at the time of collecting information.
  • Patients or family carers who are able to comprehend and communicate.
  • Cancer diagnosed and treated at AIIMS, at least 3 months before entry into the study.

Exclusion Criteria:

  • Patients who refuse to provide informed consent for this study.
  • Patients treated for cancer outside AIIMS.
  • Patients who have recurrence or disease failure for which they are or are not receiving salvage therapy.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

Coorti e interventi

Gruppo / Coorte
Adult Cancer Survivors

Intervention:

Behavioural:

Questionnaires for patient/family caregiver interview

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
To study the cancer survivorship experience(as binary responses)
Lasso di tempo: 1 year
Behavioral: Questionnaires and medical records. The cancer survivors' physical, social, economic and psychological issues will be assessed as verbal response.The survey questionnaires will document the sequelae of cancer and its treatment during the face to face interview and by collecting information from the individual cancer survivor's medical records
1 year
To assess the mental status of cancer survivors
Lasso di tempo: 1 year
Behavioral:MINI-international neuro-psychiatric questionnaire(modified for local use)
1 year

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
To identify the differences if any, in the cancer survivorship issues by age(Less than 50 or greater than 50 years)
Lasso di tempo: up to 6 months after patient accrual
This cancer survivorship survey will include adult cancer survivors post-therapy. Survivors of various neoplasms will be accrued for this survey.
up to 6 months after patient accrual
To define follow up care for cancer survivors in India.
Lasso di tempo: up to 6 months after patient accrual

This survey of 200 adult cancer survivors will analyse various issues-physical, social, psychological and economic which adversely impact the life of cancer survivors in India.

This analysis will help in evolving a feasible approach towards implementation of follow up care practice for cancer survivors.

up to 6 months after patient accrual

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Cattedra di studio: BIDHU K MOHANTI, MD, All India Institute of Medical Sciences, New Delhi
  • Direttore dello studio: Jaspreet Kaur, MD, All India Institute of Medical Sciences, New Delhi
  • Direttore dello studio: Sudhir K Khandelwal, MD, All India Institute of Medical Sciences, New Delhi
  • Direttore dello studio: Ravindra M Pandey, PhD, All India Institute of Medical Sciences, New Delhi

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio

1 gennaio 2011

Completamento primario (Anticipato)

1 luglio 2013

Completamento dello studio (Anticipato)

1 dicembre 2013

Date di iscrizione allo studio

Primo inviato

24 febbraio 2011

Primo inviato che soddisfa i criteri di controllo qualità

24 febbraio 2011

Primo Inserito (Stima)

25 febbraio 2011

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Stima)

12 luglio 2012

Ultimo aggiornamento inviato che soddisfa i criteri QC

11 luglio 2012

Ultimo verificato

1 luglio 2012

Maggiori informazioni

Termini relativi a questo studio

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Prove cliniche su Cancro

3
Sottoscrivi